An Ozempic successor falls short, Eli Lilly's GLP-1 pill, and senators grill RFK: Pharma news roundup
An Eli Lilly exec said the company’s experimental weight-loss pill could make GLP-1 treatments more accessible worldwide, as ...
Here’s why Ozempic maker’s new weight-loss drug isn’t good enough for investors
New trial data showed CagriSema led to “superior” weight loss, but at a rate much less than original expectations of 25%.
Eli Lilly's first weight loss pill could expand access to GLP-1s around the globe, executive says
Eli Lilly (LLY) believes its experimental weight-loss pill could make GLP-1 treatments more accessible worldwide.
Novo Nordisk Stock Drops on New Obesity Drug Findings. Eli Lilly Stands to Gain.
The Danish company said the average weight loss was 15.7% for the new drug, CagriSema. The expectation had been about 25%.
EL PAÍS English7d
New anti-obesity drugs already outperform Ozempic
The pharmaceutical industry is not stopping there. There are already 100 new drug candidates in trials, all vying for a slice ...
US judge denies injunction, restricting copies of Lilly weight-loss drug
A U.S. federal judge has refused to allow compounding pharmacies to keep making copies of Eli Lilly's popular weight-loss and ...
Is Eli Lilly Stock a Buy?
Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.
Medical Marketing & Media3d
Novo Nordisk welcomes patients to the Ozempic Era
With semaglutide shortages in the rearview, Novo Nordisk is doubling down on marketing efforts for its GLP-1 drugs.
PSA: The 'Ozempic Dupes' Are Coming, and They Might Work Even Better
Kennedy Jr., who was tapped to lead the Department of Health and Human Services for the Trump administration, recently ...
Fierce Healthcare7d
Eli Lilly expands telehealth access to low-cost Zepbound with Teladoc Health, LifeMD tie-ups
Eli Lilly partnered up with telehealth providers LifeMD and Teladoc Health to offer its lower cost, single-vial ...
Ozempic maker says its Australian market could be half the population
Novo Nordisk says many Australians would be willing to pay the out-of-pocket costs for its blockbuster medicines, which can ...
Nasdaq3d
Is Eli Lilly Stock a Buy?
Like many pharma stocks, Eli Lilly (NYSE: LLY ... commercialized as Ozempic and Wegovy. These drugs all have produced impressive results in clinical trials and in the real world, and that has ...